Literature DB >> 30335142

Long-term Quality of Life in Adult Patients Surviving Purpura Fulminans: An Exposed-Unexposed Multicenter Cohort Study.

Damien Contou1,2,3, Florence Canoui-Poitrine4,5, Rémi Coudroy6, Sébastien Préau7, Martin Cour8, François Barbier9, Nicolas Terzi10, Guillaume Schnell11, Arnaud Galbois12, Lara Zafrani13, Benjamin Zuber14, Stephan Ehrmann15, Elodie Gelisse16, Delphine Colling17, Matthieu Schmidt18, Samir Jaber19, Alexandre Conia20, Romain Sonneville21, Gwenhaël Colin22, Laurent Guérin23, Damien Roux24, Sébastien Jochmans25, Nancy Kentish-Barnes26, Etienne Audureau4,5, Richard Layese4,5, Aline Alves1, Rachida Ouedraogo1, Christian Brun-Buisson1, Armand Mekontso Dessap1,3, Nicolas de Prost1,3.   

Abstract

BACKGROUND: Long-term health-related quality of life (HR-QOL) of patients surviving the acute phase of purpura fulminans (PF) has not been evaluated.
METHODS: This was a French multicenter exposed-unexposed cohort study enrolling patients admitted in 55 intensive care units (ICUs) for PF from 2010 to 2016. Adult patients surviving the acute phase of PF (exposed group) were matched 1:1 for age, sex, and Simplified Acute Physiology Score II with septic shock survivors (unexposed group). HR-QOL was assessed during a phone interview using the 36-Item Short-Form Health Survey (SF-36) questionnaire, the Hospital Anxiety and Depression (HAD) scale, the Impact of Event Scale-Revised (IES-R), and the activity of daily living (ADL) and instrumental ADL (IADL) scales. The primary outcome measure was the physical component summary (PCS) of the SF-36 questionnaire.
RESULTS: Thirty-seven survivors of PF and 37 of septic shock were phone-interviewed at 55 (interquartile range [IQR], 35-83) months and 44 (IQR, 35-72) months, respectively, of ICU discharge (P = .23). The PCS of the SF-36 was not significantly different between exposed and unexposed patients (median, 47 [IQR, 36-53] vs 54 [IQR, 36-57]; P = .18). There was also no significant difference between groups regarding the mental component summary of the SF-36, and the HAD, IES-R, ADL and IADL scales. Among the 37 exposed patients, those who required limb amputation (n = 12/37 [32%]) exhibited lower PCS (34 [IQR, 24-38] vs 52 [IQR, 42-56]; P = .001) and IADL scores (7 [IQR, 4-8] vs 8 [IQR, 7-8]; P = .021) compared with nonamputated patients.
CONCLUSIONS: Long-term HR-QOL does not differ between patients surviving PF and those surviving septic shock unrelated to PF. Amputated patients have an impaired physical HR-QOL but a preserved mental health. CLINICAL TRIALS REGISTRATION: NCT03216577.
© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  SF-36; outcome; purpura fulminans; quality of life; septic shock

Mesh:

Year:  2019        PMID: 30335142     DOI: 10.1093/cid/ciy901

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  3 in total

1.  Diagnostic yield of lumbar puncture in adult patients with purpura fulminans.

Authors:  Damien Contou; Romain Sonneville; Armand Mekontso Dessap; Nicolas de Prost
Journal:  Intensive Care Med       Date:  2019-07-05       Impact factor: 17.440

2.  Identifying clinical subtypes in sepsis-survivors with different one-year outcomes: a secondary latent class analysis of the FROG-ICU cohort.

Authors:  Sabri Soussi; Divya Sharma; Peter Jüni; Gerald Lebovic; Laurent Brochard; John C Marshall; Patrick R Lawler; Margaret Herridge; Niall Ferguson; Lorenzo Del Sorbo; Elodie Feliot; Alexandre Mebazaa; Erica Acton; Jason N Kennedy; Wei Xu; Etienne Gayat; Claudia C Dos Santos
Journal:  Crit Care       Date:  2022-04-21       Impact factor: 19.334

3.  Clinical phenotype and outcomes of pneumococcal versus meningococcal purpura fulminans: a multicenter retrospective cohort study.

Authors:  Damien Contou; Nicolas de Prost
Journal:  Crit Care       Date:  2021-11-11       Impact factor: 9.097

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.